Evidence map›Paper›PMID 36237199›Full record

ArticleVaccine: X2022

Could a

Karoun H Bagamian, Chloe Puett, John D Anderson, Farzana Muhib, Clint Pecenka, Jere Behrman, Robert F Breiman, Ijeoma Edoka, Susan Horton, Gagandeep Kang and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine: X, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. mBio · 2025
    Article
  4. Article
  5. Reassessing potential economic value and health impact of effectiveBulletin of the World Health Organization · 2024
    Article
  6. ExploringVaccine: X · 2023
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 15 institutions in 7 countries.

Karoun H BagamianBagamian Scientific Consulting, LLC, Gainesville, FL 32601, USA.
Chloe PuettStony Brook University, Department of Family, Population & Preventative Medicine, Program in Public Health, Stony Brook, NY 11794, USA.
John D AndersonBagamian Scientific Consulting, LLC, Gainesville, FL 32601, USA.
Farzana MuhibCenter for Vaccine Innovation and Access, PATH, 455 Massachusetts Ave NW, Washington, DC 20001, USA.
Clint PecenkaCenter for Vaccine Innovation and Access, PATH, Seattle, WA 98121, USA.
Jere BehrmanDepartment of Economics and Sociology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Robert F BreimanHubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA.
Ijeoma EdokaHealth Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Susan HortonSchool of Public Health Sciences, University of Waterloo, Waterloo, ON N2L 3G1, Canada.
Gagandeep KangDivision of Gastrointestinal Sciences, Christian Medical College, Vellore 632004, India.
Karen L KotloffDepartment of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Claudio F LanataInstituto de Investigacion Nutricional, Lima, Peru.
James A Platts-MillsDivision of Infectious Diseases & International Health, University of Virginia, Charlottesville, VA 22903, USA.
Firdausi QadriInternational Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Elizabeth T Rogawski McQuadeDepartment of Epidemiology, Emory University, Atlanta, GA 30322, USA.
Christopher SudfeldDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
Pascale VonaeschDepartment of Fundamental Microbiology, University of Lausanne, Switzerland.
Thomas F WierzbaDepartment of Internal Medicine, Section on Infectious Diseases, Winston-Salem, NC 27157, USA.
Suzanne ScheeleCenter for Vaccine Innovation and Access, PATH, 455 Massachusetts Ave NW, Washington, DC 20001, USA.
Program for Appropriate Technology in Health · USEmory University · USChristian Medical College, Vellore · INHarvard Global Health Institute · USInstituto de Investigación Nutricional · PEInternational Centre for Diarrhoeal Disease Research · BDScientific Consulting Group · USStony Brook University · USUniversity of Florida Health · USUniversity of Lausanne · CHUniversity of Maryland, Baltimore · USUniversity of Pennsylvania · USUniversity of the Witwatersrand · ZAUniversity of Virginia · USUniversity of Waterloo · CA

Funding

Bill & Melinda Gates Foundation INV-018460Wellcome Trust
6 · The paper itself

Abstract

Shigellosis is a leading cause of diarrhea and dysentery in young children from low to middle-income countries and adults experiencing traveler's diarrhea worldwide. In addition to acute illness, infection by

Indexed as

Childhood diarrheaCost-benefitEconomic modelGrowth falteringShigellastuntingVaccine

Identifiers

PMID36237199
PMCPMC9551074
OpenAlexW4296657753

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.